An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Recruiting now
Conditions studied: Adverse Pregnancy Outcomes, Atopic Dermatitis
In brief
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Key facts
- Study ID
- NCT03936335
- Run by
- Regeneron Pharmaceuticals
- People needed
- 3930
- Starts
- 2019-09-30
- Expected to finish
- 2027-01-21
- Last updated by the study team
- 2025-08-03
Who can join
Age: 18 and older, up to 49. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Regeneron Research Site — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.